Prof. Grandi led the Biotechnology Centers of the Italian energy company ENI for several years, directing pioneering research in recombinant biopharmaceuticals and environmentally friendly production of chemicals using protein engineering. He subsequently joined Chiron as Director of the Molecular Biology and Biochemistry Department within the Vaccines Division in Siena, Italy. Following Chiron’s acquisition by Novartis, he became Senior Project Leader, playing a pivotal role in the development of innovative human vaccines.
In 2015, Prof. Grandi transitioned to academia as Full Professor of Microbiology and Clinical Microbiology. Since then, his research has focused on the design of an innovative vaccine platform based on bacterial outer membrane vesicles (OMVs) and its application in vaccines for infectious diseases and cancer immunotherapy. Prof. Grandi is also a co-founder of the biotechnology company BiOMViS Srl, whose mission is to advance human and animal health through the development of novel OMV-based therapeutic and prophylactic products.